Markets

Surging Earnings Estimates Signal Good News for Sagent Pharmaceuticals (SGNT) - Tale of the Tape

Sagent Pharmaceuticals, Inc. ( SGNT ), a pharmaceutical company that develops, sources, manufactures and markets pharmaceutical products could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.

These positive earnings estimate revisions suggest that analysts are becoming more optimistic on SGNT's earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames, suggesting that Express could be a solid choice for investors.

Current Quarter Estimates for SGNT

In the past 30 days, 1 estimate has gone higher for Sagent Pharmaceuticals while there is no downward estimates revision in the same time period. Estimates however remained flat at a loss of 4 cents a share in the past 30 days.

Current Year Estimates for SGNT

Meanwhile, Sagent Pharmaceuticals' current year figures are also looking quite promising, with 2 estimates moving higher in the past month. The consensus estimate trend has also seen a boost for this time frame, increasing from 27 cents a share 30 days ago to 31 cents per share today, an increase of 14.8%.

Bottom Line

The stock has also started to move higher lately, adding 10% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #2 (Buy) stock to profit in the near future.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

SAGENT PHARMA (SGNT): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.